Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3924590 | 0.90 | HSD11B1 (0.42) | USP2CYP2C19CYP2D6CYP2C9CYP3A4 | |
| SCHEMBL751237 | 0.90 | USP2 (0.39) | USP2CYP2C19CYP2D6CYP2C9CYP3A4 | |
| Hydrochloric Acid SCHEMBL8486057 | 0.87 | HSD11B1 (0.41) | USP2CYP2C19CYP2D6CYP2C9CYP3A4 | |
| SCHEMBL4062010 | 0.87 | HSD11B1 (0.45) | USP2CYP2C19CYP2C9CYP3A4CYP1A2 | |
| SCHEMBL27038832 | 0.85 | CYP1A2 (0.47) | USP2CYP2C19CYP2D6CYP2C9CYP3A4 | |
| SCHEMBL20564178 | 0.85 | CYP2D6 (0.38) | USP2CYP2C19CYP2D6CYP2C9CYP3A4 | |
| SCHEMBL30501211 | 0.85 | USP2 (0.37) | USP2CYP2C19CYP2D6CYP2C9CYP3A4 | |
| SCHEMBL29418104 | 0.84 | HSD11B1 (0.42) | USP2CYP2C19CYP3A4MAPK1ALDH1A1 | |
| SCHEMBL485154 | 0.84 | CYP1A2 (0.56) | USP2CYP2C19CYP2D6ALDH1A1CYP1A2 | |
| SCHEMBL2168327 | 0.84 | USP2 (0.36) | USP2CYP2C19CYP2D6CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4244208-B1 | A MAGL INHIBITOR | H LUNDBECK AS (DK) | 2025-04-02 | — | — | EP | claimed |
| EP-4244208-A1 | A MAGL INHIBITOR | H. Lundbeck A/S (DK) | 2023-09-20 | — | — | EP | claimed |
| US-11434222-B2 | MAGL inhibitors | H. LUNDBECK A/S (DK) | 2022-09-06 | — | — | US | claimed |
| WO-2022101412-A1 | A MAGL INHIBITOR | H. LUNDBECK A/S (DK) | 2022-05-19 | — | — | WO | claimed |
| EP-2032535-B1 | SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS | SANOFI SA (FR) | 2012-08-01 | — | — | EP | claimed |
| EP-2032535-A1 | SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS | Sanofi-Aventis (FR) | 2009-03-11 | — | — | EP | claimed |
| WO-2007137738-A1 | SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS | SANOFI-AVENTIS (DE) | 2007-12-06 | — | — | WO | claimed |
| EP-4574150-A2 | A MAGL INHIBITOR | H. Lundbeck A/S (DK) | 2025-06-25 | — | — | EP | disclosed |
| EP-4244208-B1 | A MAGL INHIBITOR | H LUNDBECK AS (DK) | 2025-04-02 | — | — | EP | disclosed |
| EP-3788043-B1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME LLC (US) | 2024-11-06 | — | — | EP | disclosed |
| CN-116322700-B | Novel PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2024-08-20 | — | — | CN | disclosed |
| US-11976069-B2 | Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection | MERCK SHARP & DOHME LLC (US) | 2024-05-07 | — | — | US | disclosed |
| US-20240018120-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2024-01-18 | — | — | US | disclosed |
| EP-2486042-A1 | BICYCLIC HETEROCYCLES AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2012-08-15 | — | — | EP | disclosed |
| EP-2032535-B1 | SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS | SANOFI SA (FR) | 2012-08-01 | — | — | EP | disclosed |
| EP-2454252-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | Rottapharm S.p.A. (IT) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011042399-A1 | BICYCLIC HETEROCYCLES AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011006960-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | ROTTAPHARM S.P.A. (IT) | 2011-01-20 | — | — | WO | disclosed |
| EP-2032535-A1 | SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS | Sanofi-Aventis (FR) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007137738-A1 | SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS | SANOFI-AVENTIS (DE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11434222-B2 | MAGL inhibitors | MAG, MAGI3, MAGT1 | USP2 1558/4885CYP2C19 4788/4885CYP2D6 2791/4885 |
| US-20240018120-A1 | MAGL INHIBITORS | MAG, MAGI3, MAGT1 | USP2 1558/4885CYP2C19 4788/4885CYP2D6 2791/4885 |
| US-11976069-B2 | Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection | HDAC1, HDAC11, HDAC2 | USP2 1891/4885CYP2C19 1235/4885CYP2D6 2148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.